2021
DOI: 10.1080/13543784.2021.1957830
|View full text |Cite
|
Sign up to set email alerts
|

Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
28
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 45 publications
(28 citation statements)
references
References 45 publications
0
28
0
Order By: Relevance
“…Although limited drugs, such as GnRH ( Dababou et al, 2021 ), mifepristone ( Bi et al, 2021 ), are widely used in the treatment of UF, they lack a well-defined target and always bring patients side-effects (for example, recidivation after drug withdrawal). Therefore, target drugs for UF urgently need to be discovered to avoid physical injury caused by hysterectomy.…”
Section: Discussionmentioning
confidence: 99%
“…Although limited drugs, such as GnRH ( Dababou et al, 2021 ), mifepristone ( Bi et al, 2021 ), are widely used in the treatment of UF, they lack a well-defined target and always bring patients side-effects (for example, recidivation after drug withdrawal). Therefore, target drugs for UF urgently need to be discovered to avoid physical injury caused by hysterectomy.…”
Section: Discussionmentioning
confidence: 99%
“…In recent years, some literature has mentioned that Vilaprisan is used in the treatment of perimenopausal women. Compared with GnRH-a, Vilaprisan may have a better effect with lower side effects ( 43 , 44 ). However, this kind of drug is not widely used in China, so GnRH-a is still used in this study, which is also one of the shortcomings of this paper.…”
Section: Discussionmentioning
confidence: 99%
“…In addition to the identification of susceptible individuals [ 7 , 18 , 20 , 21 ], insights into the molecular aspects of UL could assist in the development of targeted therapies. Several clinical management options for ULs are available and some are under investigation [ 33 , 34 ]. Current treatment options for UL could be improved by incorporating the molecular information on UL.…”
Section: Discussionmentioning
confidence: 99%